Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival

21 Oct 2022

Abstract excerpt

Breast cancer ranks first in terms of mortality and incidence rates worldwide among women. The HER2+ molecular subtype is one of the most aggressive subtypes; its treatment includes neoadjuvant chemotherapy and the use of a HER2 antibody. Some patients develop resistance despite positive results obtained using this therapeutic strategy. OBJECTIVE: To identify prognostic markers for treatment and survival in HER2+...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to HER2/EGFR in Cancer Research
Share to S100 Proteins and Annexins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36338974
DOI: 10.3389/fgene.2022.991706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survivalPMID 36338974Read ↗

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance BiomarkersSemantic proximity Read ↗

Transcriptomic analysis of breast cancer patients sensitive and resistant to chemotherapy: Looking for overall survival and drug resistance biomarkersSemantic proximity Read ↗

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read ↗

Identification of a novel gene signature with DDR and EMT difunctionalities for predicting prognosis, immune activity, and drug response in breast cancerSemantic proximity Read ↗

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity Read ↗

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancerSemantic proximity Read ↗

A novel twelve-gene signature to evaluate neoadjuvant chemotherapy response and predict prognosis in breast cancerSemantic proximity Read ↗

Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancerSemantic proximity Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

Identification of DDIT4 as a Potential Prognostic Marker Associated with Chemotherapy and Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Key Genes and Prognostic Analysis in HER2+ Breast CancerSemantic proximity Read ↗

The construction of a breast cancer prognostic model by combining genes related to hypoxia and endoplasmic reticulum stress.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.